ABVC BioPharma, Inc. (ABVC) can sell. Click on Rating Page for detail.
The price of ABVC BioPharma, Inc. (ABVC) is 0.524 and it was updated on 2024-12-21 07:00:43.
Currently ABVC BioPharma, Inc. (ABVC) is in undervalued.
News |
---|
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
|
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
|
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
|
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
|
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
|
StockPrice Release |
---|
Abvc biopharma announces reverse stock split
|
Abvc biopharma provides 2023 pipeline update
|
Abvc provides oncology pipeline updates
|
Abvc biopharma provides vitargus® update
|
Abvc biopharma provides vitargus® update
|
Abvc biopharma provides vitargus® update
|
Abvc biopharma report updated by zacks/scr
|
Abvc biopharma provides vitargus® update
|
News |
---|
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
|
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
|
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
|
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
|
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
|
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
|
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
|
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
|
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
|
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
|
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
|
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
|
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
|
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
|
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
|
ABVC Executes Cooperation Agreement for Strategic Investments
|
How to Find Cheap Penny Stocks to Make Money Trading
|
5 Hot Penny Stocks Exploding After News This Week
|
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
|
ABVC Biopharma Stock (ABVC): Why The Price Increased
|
Why ABVC BioPharma Shares Are Trading Higher On Friday?
|
Hot Reddit Penny Stocks to Watch That Exploded Today
|
ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today
|
ABVC Biopharma stock is up 275% on Monday: explained here
|
ABVC Stock: Why The Price Surged Today
|
ABVC Stock: Why The Price Increased Today
|
ABVC Stock: Why It Increased Today
|
ABVC Stock: Over 40% Increase Pre-Market Explanation
|
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments
|
ABVC BioPharma Report Updated by Zacks/SCR
|
ABVC Stock: Over 28% Increase Explanation
|
ABVC BioPharma Provides Vitargus® Update
|
ABVC BioPharma Reports Second Quarter 2021 Results
|
ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering
|
American BriVision: Deep Dive Into Market Potential
|